CORT vs XERS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CORT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CORT and XERS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CORT and XERS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026.

Full CORT guide

Xeris Biopharma Holdings is a Chicago-based biopharmaceutical company that sells three approved medicines in the US. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor for adults with endogenous hypercortisolemia, the hormonal condition behind Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon, sold as a prefilled syringe and autoinjector (HypoPen), for severe low blood sugar in people with diabetes. Keveyis (dichlorphenamide) treats primary periodic paralysis, a rare muscle disorder. Two of the three came from the 2021 Strongbridge Biopharma acquisition, and the company also owns a formulation platform (XeriSol and XeriJect) that turns drugs into stable, non-aqueous injectables, which underpins its pipeline candidate XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism.

Full XERS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CORT drivers: Cushing's / hypercortisolism growth runway; Relacorilant as the next-generation successor.
• XERS drivers: Recorlev demand in an underdiagnosed disease; Margin expansion and operating leverage.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue concentration is the defining risk: Korlym still drives most of the business, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. For XERS, concentration is the central risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CORT if you believe its drivers more; XERS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CORT and XERS guides.

CORT. Corcept swung from a Q1 2026 net loss of roughly $31 million, driven by Lifyorli launch spending, to a ~$42 million profit in Q2 on record revenue, so the trailing P/E above 200x mostly reflects depressed recent earnings. On forward numbers the picture is different: analysts expect about $4.41 of EPS in 2027, which puts the stock near 25x, a growth-and-optionality premium that leaves little room for a slower launch. Gross margin near 98% means incremental revenue drops through quickly once launch costs level off.

XERS. At about $2.0B in market value and roughly $2.1B to $2.2B in enterprise value, XERS trades near 6x trailing revenue and about 5.5x the midpoint of 2026 guidance. The trailing P/E is not meaningful because the June quarter included a ~$31M non-cash charge from the convertible note exchange, which pushed reported results to a loss. Investors are effectively valuing the company on revenue growth and EBITDA trajectory, with Recorlev doing most of the work, and treating XP-8121 as an option whose value depends on a Phase 3 readout expected around late 2028.

Headline figures (approximate, October 2026): CORT shows revenue (ttm) ~$831M; Q2 2026 +31.7% YoY, fy2025 revenue ~$761M, fy2026 revenue guidance (raised earlier in 2026) ~$950M to $1.05B; consensus ~$1.15B, net income (ttm) ~$54M (EPS ~$0.45); XERS shows revenue (ttm) ~$335M (June 2026 quarter ~$92.1M, +29% YoY), 2026 revenue guidance ~$385M to $390M (+32% to +34%), adjusted ebitda (h1 2026) ~$34.4M (FY2025 ~$59.4M), gross margin (q2 2026) ~86%.

CORT and XERS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CORT and XERS exposure against your real portfolio. It is not an investment adviser.